Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT05856383
Status
Recruiting
Apply to this trial

Conditions

  • HER2-positive Advanced Breast Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.

Key Dates

Start date
Mar 16, 2022
Status verified
May 2023
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Group of ues of inetetamab combined with pyrotinib and vinorelbine
    Group of ues of inetetamab combined with pyrotinib and vinorelbine

Primary Outcome Measure

Progressive free survival(PFS) [ Time Frame: From date of treatment of inetetamab combined with pyrotinib and vinorelbine until the date of the progression of the tumor or death from any cause, whichever came first, assessed up to about 48 months ]

Central Contacts

Related Studies